A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

Shortages will affect non-pen injectable insulins through early weeks of April Over six million Americans rely on specific ...

Eli Lilly is advancing its diabetes and obesity treatment with an oral drug, orforglipron. In an exclusive interaction, CEO ...

Mounjaro is a very big opportunity, given that a significant number of people have diabetes in India, says the CEO ...

GLP-1 receptor agonists, originally introduced in 2006, have undergone significant advancements over the years. David Ricks, ...